Announcement of the Establishment of the Nucleic Acid Medicine API Development Center
Ajinomoto Bio-Pharma Services and Gene Design will enhance its contract development and production system from the early stages of development to late stages and commercialization by introducing large-scale production facilities.
The establishment of the new base will expand the production volume per lot to the kilogram level. By combining our production capacity with the mass production technology of the Ajinomoto Group, a flexible and seamless supply system capable of producing over 100 kg, as opposed to the conventional μg manufacturing, will be established.

Inquiry about this news
Contact Us Online




